article thumbnail

This Common Artificial Sweetener Can Break Down DNA, Scientists Warn

AuroBlog - Aurous Healthcare Clinical Trials blog

The artificial sweetener sucralose (marketed as Splenda) is widely used and found in products like diet soda and chewing gum. According to a new study, it’s also capable of damaging the DNA material inside our cells.

DNA 189
article thumbnail

DNA Cloning Market: A Step Towards Future of Genetics Science

Roots Analysis

DNA cloning is the field of synthetic biology which can be helpful to understand the effect of mutation on a particular gene. Many diseases that can be treated using DNA cloning, such as leukemia and sickle cell anemia, involving the replacement of defected gene. DNA Cloning Kit Providers – Current Market Landscape.

DNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading innovators in genetically modified animal models for the pharmaceutical industry

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models.

Genetics 130
article thumbnail

Eurofins to Acquire DNA Diagnostics Center to Grow Genetic Testing Capabilities and Significantly Expand Further Into the Consumer Testing Market

BioTech 365

Eurofins to Acquire DNA Diagnostics Center to Grow Genetic Testing Capabilities and Significantly Expand Further Into the Consumer Testing Market Eurofins to Acquire DNA Diagnostics Center to Grow Genetic Testing Capabilities and Significantly Expand Further Into the Consumer Testing Market … Continue reading →

DNA 52
article thumbnail

Merck KGaA signs DNA damage response cancer deal with Artios Pharma

pharmaphorum

Germany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel DNA damage response targets in cancer. The principle of DNA damage response is already being exploited by AstraZeneca and other companies with their poly (ADP-ribose) polymerase (PARP) inhibitor drugs.

DNA 94
article thumbnail

STAT+: Pacific Biosciences, known for niche DNA sequencing, looks to rival Illumina with new product launch

STAT News

firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.

DNA 98
article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98